

Jinqiao Qian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/518479/publications.pdf>

Version: 2024-02-01

19
papers

410
citations

687363

13
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

604
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexmedetomidine exerts cardioprotective effect through miR-146a-3p targeting IRAK1 and TRAF6 via inhibition of the NF- κ B pathway. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110993.	5.6	25
2	Dexmedetomidine preconditioning mitigates myocardial ischemia/reperfusion injury via inhibition of mast cell degranulation. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111853.	5.6	12
3	Implication of regulatory networks of long noncoding RNA/circular RNA-miRNA-mRNA in diabetic cardiovascular diseases. <i>Epigenomics</i> , 2020, 12, 1929-1947.	2.1	8
4	Oxytocin mediated cardioprotection is independent of coronary endothelial function in rats. <i>Peptides</i> , 2020, 130, 170333.	2.4	3
5	Oxytocin ameliorates ischemia/reperfusion-induced injury by inhibiting mast cell degranulation and inflammation in the rat heart. <i>Biomedicine and Pharmacotherapy</i> , 2020, 128, 110358.	5.6	15
6	Dexmedetomidine protects H9C2 against hypoxia/reoxygenation injury through miR-208b-3p/Med13/Wnt signaling pathway axis. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 110001.	5.6	18
7	Dexmedetomidine alleviates H ₂ O ₂ -induced oxidative stress and cell necroptosis through activating of β 2-adrenoceptor in H9C2 cells. <i>Molecular Biology Reports</i> , 2020, 47, 3629-3639.	2.3	18
8	The administration of dexmedetomidine changes microRNA expression profiling of rat hearts. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109463.	5.6	13
9	Involvement of miR-665 in protection effect of dexmedetomidine against Oxidative Stress Injury in myocardial cells via CB2 and CK1. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108894.	5.6	28
10	Dexmedetomidine preconditioning attenuates ischemia/reperfusion injury in isolated rat hearts with endothelial dysfunction. <i>Biomedicine and Pharmacotherapy</i> , 2019, 114, 108837.	5.6	24
11	Uncovering novel landscape of cardiovascular diseases and therapeutic targets for cardioprotection via long noncoding RNA-miRNA-mRNA axes. <i>Epigenomics</i> , 2018, 10, 661-671.	2.1	56
12	Risks of Impaired Organ Protection with Inhibiting Transient Receptor Potential Vanilloid 1. <i>Anesthesiology</i> , 2018, 129, 377-378.	2.5	1
13	Circulating miRNA Expression Profiling and Target Prediction in Patients Receiving Dexmedetomidine. <i>Cellular Physiology and Biochemistry</i> , 2018, 50, 552-568.	1.6	18
14	Alelitazar, a dual peroxisome proliferator-activated receptor- α and - β agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 152-162.	2.0	8
15	Alelitazar, a Balanced Dual PPAR α and - β Agonist, Protects the Heart Against Ischemia-Reperfusion Injury. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 129-141.	2.6	11
16	Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000227.	2.8	64
17	Regulation of phosphatase and tensin homolog on chromosome 10 in response to hypoxia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H1806-H1817.	3.2	20
18	Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR- β -independent manner. <i>Basic Research in Cardiology</i> , 2011, 106, 431-446.	5.9	42

#	ARTICLE	IF	CITATIONS
19	Impact of HMGâ€CoA reductase inhibition on oxidantâ€induced injury in human retinal pigment epithelium cells. Journal of Cellular Biochemistry, 2011, 112, 2480-2489.	2.6	23